STERIS
Infection Prevention Technologies

June 25, 2020

To Our Valued Customers:

The SARS-CoV-2 Coronavirus pandemic has created unprecedented challenges for patient care and staff safety. As your partner for infection prevention, we have been working with regulators to try to find solutions to your most pressing needs.

The U.S. FDA has granted STERIS an Emergency Use Authorization. This allows STERIS to temporarily provide a distinct option to effectively decontaminate compatible N95 (e.g. FFP2) respirators **up to 10 times** using the **Non Lumen Cycle of the V-PRO™ Low Temperature Sterilization System** (Models: 1 Plus, maX maX 2, 60 and s2).

Testing demonstrated effective decontamination of compatible N95 respirators inoculated with a surrogate virus that is more resistant than SARS-CoV-2 Coronavirus. Studies also demonstrated that reprocessing does not impact the function of the respirators or alter the materials of construction.

Compatible N95 respirators include:

- Respirators that are NIOSH Approved
- Respirators with no exhalation valves
- Respirators that do not contain cellulose-based materials
- Respirators that are Non-NIOSH-approved, except for Non-NIOSH approved respirators manufactured in China.

To help navigate Healthcare Customers through this process, STERIS has created a COVID-19 landing page which includes information on how to prepare the respirators for decontamination in the aforementioned V-PRO™ Low Temperature Sterilization Systems.

General information is also included on STERIS modalities related to SARS-CoV-2 Coronavirus.

If you have specific questions, please contact your STERIS Account Manager, Clinical Specialist and/or submit your questions directly to STERIS.

STERIS remains committed to your success in delivering patient care through this pandemic. Thank you for all that you are doing to serve patients.

Best Regards,

STERIS
Infection Prevention Technologies